This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
partially because its key riskfactor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heart attack or stroke. About the Study The study evaluated engagement and clinical outcomes among age 65+ participants of an mHealth app-based CV risk self-management program.
In organ transplantation, an extended criteria donor is defined as having perceived riskfactors linked to poor subsequent outcomes, for example, those with age >55 or ischemic times exceeding 4 hours, which sometimes leads to rejection of the donor organ.
This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November. This is the first PFA technology to receive FDA approval and follows the recent European CE (Conformité Européenne) Mark of the PulseSelect PFA system in November.
tim.hodson Sat, 12/09/2023 - 15:35 On Jan. However, conversations are ongoing around best practices and standards of care regarding contrast management and treatment for those with higher riskfactors, like compromised renal function. Review riskfactors determining higher risk populations.
mg tablets), together with Caristo Diagnostics , a leading cardiac disease diagnostics company with the novel CaRi-Heart technology to visualize and quantify coronary inflammation, announced today their collaboration to improve awareness and clinical education about the central role of inflammation in coronary artery disease. mg tablets.”
tim.hodson Mon, 03/31/2025 - 15:02 March 31, 2025 iRhythm Technologies, Inc. Treasure Island (FL): StatPearls Publishing; June 5, 2023. Atrial fibrillation as an independent riskfactor for stroke: The Framingham Study. iRhythm Technologies, 2025. iRhythm Technologies, 2024. 3 Desai et al. Arrhythmias.
milla1cf Wed, 12/13/2023 - 10:24 December 13, 2023 — A new artificial intelligence (AI) model designed by Scripps Research scientists could help clinicians better screen patients for atrial fibrillation (or AFib)—an irregular, fast heartbeat that is associated with stroke and heart failure.
tim.hodson Sat, 12/09/2023 - 15:35 On Jan. However, conversations are ongoing around best practices and standards of care regarding contrast management and treatment for those with higher riskfactors, like compromised renal function. Review riskfactors determining higher risk populations.
Conavi ( www.conavi.com ) is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Conavi is an exciting commercial-stage company with groundbreaking technology and an accomplished management team.
The report identifies several pathways to begin to narrow the gap, including: Expanding women-focused research, accelerating translation of findings and facilitating the commercialization of products and technologies to improve women's health. billion in healthcare venture funding in 2023.
2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib.4 Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of riskfactors: cohort study based on longitudinal data from the Framingham Heart Study. Epidemiology of Atrial Fibrillation in the 21st Century.
milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. billion adults worldwide.
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionThis study evaluates the feasibility of a survivor‐centric, navigator‐driven, and technology‐enabled platform supporting survivors and care partners in post‐stroke recovery.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content